| Serial Number | 97135396 |
| Word Mark | PINOVA THERAPEUTICS |
| Filing Date | Friday, November 19, 2021 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Saturday, March 2, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 18, 2023 |
| Goods and Services | pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty |
| Goods and Services | medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty |
| Disclaimer with Predetermined Text | "THERAPEUTICS" |
| Goods and Services | scientific research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 24, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 24, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 24, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Pocket Naloxone Corp. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Bethesda, MD 20816 |
| Party Name | Pocket Naloxone Corp. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Bethesda, MD 20816 |
| Event Date | Event Description |
| Tuesday, March 5, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Saturday, March 2, 2024 | SOU EXTENSION 1 GRANTED |
| Saturday, March 2, 2024 | SOU EXTENSION 1 FILED |
| Saturday, March 2, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, September 12, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 18, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 18, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, June 28, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, June 8, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, May 11, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 11, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 11, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, April 14, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, April 14, 2023 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Friday, April 14, 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, April 14, 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, April 11, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, April 11, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, April 11, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, March 2, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, February 28, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, February 28, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, August 31, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, August 31, 2022 | NON-FINAL ACTION E-MAILED |
| Wednesday, August 31, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, August 30, 2022 | ASSIGNED TO EXAMINER |
| Wednesday, November 24, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, November 23, 2021 | NEW APPLICATION ENTERED |